2015/03/30

SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION